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Abstract
Identifying genetic factors responsible for serious adverse drug reaction (SADR) is of critical importance to personalized
medicine. However, genome-wide association studies are hampered due to the lack of case-control samples, and the
selection of candidate genes is limited by the lack of understanding of the underlying mechanisms of SADRs. We
hypothesize that drugs causing the same type of SADR might share a common mechanism by targeting unexpectedly the
same SADR-mediating protein. Hence we propose an approach of identifying the common SADR-targets through
constructing and mining an in silico chemical-protein interactome (CPI), a matrix of binding strengths among 162 drug
molecules known to cause at least one type of SADR and 845 proteins. Drugs sharing the same SADR outcome were also
found to possess similarities in their CPI profiles towards this 845 protein set. This methodology identified the candidate
gene of sulfonamide-induced toxic epidermal necrolysis (TEN): all nine sulfonamides that cause TEN were found to bind
strongly to MHC I (Cw*4), whereas none of the 17 control drugs that do not cause TEN were found to bind to it. Through an
insight into the CPI, we found the Y116S substitution of MHC I (B*5703) enhances the unexpected binding of abacavir to its
antigen presentation groove, which explains why B*5701, not B*5703, is the risk allele of abacavir-induced hypersensitivity.
In conclusion, SADR targets and the patient-specific off-targets could be identified through a systematic investigation of the
CPI, generating important hypotheses for prospective experimental validation of the candidate genes.
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Introduction
Identifying genetic risk factors responsible for serious adverse
drug reactions (SADRs) is one of the priorities in pharmacoge-
netics [1]. As it is not practical to perform genome-wide
association study due to the lack of samples [2], candidate gene
selection has been an important strategy. Challenges arise when
the primary mechanisms for many SADRs are unclear. Conse-
quently, the candidate genes selected are generally limited to those
coding therapeutic targets [3], transporters or metabolic enzymes
[4]. We named this strategy as the ‘‘known interaction driven
selection’’, for it is driven by the known interactions between drugs
and proteins. However, the drug-protein interactions at this level
cannot explain why an SADR is only induced by certain
medications but never caused by other drugs. For example,
Stevens-Johnson syndrome (SJS) is often caused by diclofenac,
didanosine and tenoxicam but never caused by propoxyphene. It
is undisputed that direct interaction between a chemical and a
protein, for example, noncovalent binding of a drug to the active
center of an enzyme, is a fundamental step in drug effect. Hence,
we hypothesized that drugs causing the same type of SADR might
share a common mechanism by targeting unexpectedly on the
same SADR-mediating protein. But questions still arise as why
after strict assessment before the drugs came to the market,
SADRs still and only happen to some certain individuals,
especially the type B or idiosyncratic SADR [5]. Evidences
showed that some rare polymorphisms within these SADR targets
made them more sensitive to the drug. For example, oseltamivir
(Tamiflu), an anti-flu drug, whose active form binds to the active
site of human cytosolic sialidase. A rare polymorphism near the
binding pocket may enhance this unexpected binding and might
increase susceptibility to oseltamivir-induced neuropsychiatric
disorders [6]. Another case concerns the A1555G mutation in
mitochondrion DNA, which enhances the unwanted binding of
aminoglycosides to human 12s rRNA, mediating the susceptibility
of aminoglycosides-induced deafness [7]. Thus, the candidate gene
selection of SADR genetics can be tackled by exploring the
unexpected chemical-protein bindings. To harvest them at high
throughput, we established the first chemical-protein interactome
(CPI) in the form of the interaction strength among FDA-
approved drugs and human proteins. Each of the drugs was
reported to cause at least one of the four major SADRs including
SJS/TEN, cholestasis, rhabdomyolysis and deafness. We designed
a data-mining strategy against the CPI to explore whether the
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share the common outcome of SADR ‘‘S’’ all interact with a
particular protein ‘‘P’’, whereas drugs that do not cause the ‘‘S’’
outcome do not interact with it, then the common target ‘‘P’’ can
be considered as a mediator of ‘‘S’’ and prioritized for association
studies and mechanism investigations.
Results
Reliability of the DOCK program based CPI in assessing
the chemical-protein interaction
Several techniques such as BIACORE biosensors [8] and drug
affinity pull-down [9] can be used to assess the chemical-protein
interactions and to identify the unexpected chemical-protein
bindings. However, in order to test the utilities of CPI in a low
cost and high throughput manner, we intended to choose a mature
technique. Dock programs [10] appeared to be a good option. The
DOCK [11] has been under development and improvement for
over 20 years and is widely used to evaluate the interaction
strength between drug candidates and proteins targets. Particu-
larly, it has previously been used to identify the unexpected
binding. A classical case is haloperidol, an anti-psychiatric drug,
which was found to bind unexpectedly to HIV protease and had
become a template for developing anti-HIV drugs [12]. The
discovery was made with DOCK, whose later version [13] was
applied in our research reported here.
Since human knowledge of the four SADRs is limited, neither
did we know any of the unintended drug-protein interactions in
them nor did we not know how many protein targets should be
enough to cover the mechanism space of them without bias. So we
selected targets from literature and third-party targetable protein
database [14–17] and then applied quality control steps as
described in the methods. Considering our productivity of pockets
preparation and the urgency of solving the SADR problem, a set
of 845 proteins (Table S1) finally passed the quality control.
Although the protein set was incompetent to cover the whole
SADR targets, if some unexpected and valuable information could
be mined from it, the methodology of CPI would enlighten the
following research and thus lead to the construction of a large scale
target set. We constructed a test CPI to test the feasibility of using
DOCK in evaluating the interactions. In our protein set, there
were 12 proteins which had been the therapeutic targets as they
were listed in DrugBank [18]. We extracted the known direct
interactions with the 12 proteins reported in DrugBank or the
literature for a total of 46 drugs. We then ran the DOCK for
466891 times, resulting in a docking score matrix with 466891
elements. The matrix was then shrunk to 466845 elements before
we converted the matrix into the Z-score [19] matrix, where
binding affinities for each drug across the 891 binding pockets
were normalized to a mean of zero and standard deviation of one,
since it has been reported that the normalization of the docking
score matrix can improve the hit ratio [20]. Docking score
distribution is dependent on sizes, charges and other characters of
the drug. The normalization could address this inconsistency
among drugs. Each drug-protein interaction was classified into one
of the two categories, depending on whether (group 1) or not
(group 2) the interaction was previously reported in DrugBank or
in the literature. Statistical test of Z-score showed that the two
groups belonged to different population (Table S2). The area
under ROC curve was 0.74 (95% CI: 0.68–0.80, Figure S1),
indicating that the Z-score was valuable in measuring true
bindings. The 50
th percentile of Z-score in group 1 interactions
was 21.240 while the 50
th percentile of group 2 was only 20.47.
We thus set a Z-score threshold of 21.2 in order to distinguish the
known bindings (group 1) from the unidentified bindings (group 2).
Note that some of the unidentified bindings might exist per se,
which would reduce the difference between two groups. However,
this misclassification of unidentified interactions into known
bindings did not affect the specificity of highlighting the true
bindings from the unidentified ones. So we concluded that Z-score
could tell whether a binding will occur at the interval of high
absolute value.
Based on the reliability of the dock program and the data
processing strategy that effectively separate known bindings from
unidentified ones, we introduce the first release of CPI in the form
of a Z-score matrix. The chemicals selected here were FDA-
approved drugs, each of which was reported to cause at least one
of the four major well-known SADRs mentioned above. The
derivatives of these drugs, such as the known major metabolites
and their known isomers were also included. In summary, the CPI
consists of the binding affinity data between 162 chemicals and
891 binding pockets. The interaction strengths were converted
into a Z-score matrix. We did not choose SADRs like
hepatotoxicity, for it is a relatively big concept compared with
cholestasis and can be induced by almost every drug. The four
SADRs included in this research were not only the major SADRs
usually reported in the FDA’s Adverse Event Reporting System
(AERS), but each of which was also appeared to be triggered by a
particular set of medications. This type of SADR allowed us to
identify ‘‘case’’ and ‘‘control’’ drugs from which clear differences
in the pattern of binding to many proteins were observed from the
CPI. In the following section, we used the SJS/TEN SADR as an
example to illustrate the construction and utilities of the CPI.
Identification of candidate genes of serious cutaneous
reactions through mining the CPI
The SJS and TEN are two forms of the same life-threatening
cutaneous reactions that cause rash, skin peeling, and sores on the
mucous membranes triggered by particular types of medications
[21] with primary mechanism unknown. No significant association
was observed between the metabolite enzyme genes and the SJS/
TEN [22], implying that ‘‘known interaction driven’’ genes might
Author Summary
Why do tragedies caused by Vioxx or Avandia only happen
to certain individuals? The unexpected bindings among
drugs and human proteins might play important roles in
such serious adverse drug reactions (SADRs). To mine
these unexpected chemical-protein interactions, 162 drug
molecules known to cause SADRs are ‘hybridized’ onto 845
proteins to construct a chemical-protein interaction matrix,
from which two aspects of the information, the binding
strength and the binding conformation, are disclosed.
Followed by the data-mining strategies, the unexpected
bindings that mediate SADRs are identified. For example,
abacavir is found to bind to the antigen presentation
groove of MHC I molecule in patients carrying the B*5701
allele but not B*5703, which explains why HLA-B*5701, not
B*5703, is the risk allele of abacavir hypersensitivity. This
research could explain to the public that SADR happens
when some of the innocent proteins are attacked by drugs
unexpectedly, and variances in certain people’s genome
make their proteins more sensitive to the drug. By pre-
therapy screening, the susceptible people could be
protected. Furthermore, new drugs or modified drugs will
be designed to avoid these patient-specific unintended
bindings, in a step toward realizing personalized medicine.
Chemical-Protein Interactome Adverse Drug Reaction
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reported to be associated with this SADR in peer-reviewed
publications. All of the drug-SJS/TEN relationships were
confirmed in the FDA’s AERS. In total, 32 drugs along with
their 21 major derivatives served as the case group, whereas 17
drugs were verified to be unrelated to SJS/TEN in both
publications and AERS and served as the control group, which
did not contain the derivatives. To avoid biases in the following
assessment, we also confirmed that they did not share the same
chemical features.
After docking all 70 molecules into all 891 binding pockets of
our set of 845 proteins (step 1 of Figure 1), we obtained a Z-score
matrix of the binding affinities. We then split it into the case
matrix (536845 relations) and the control matrix (176845
relations). We performed a hierarchical clustering [23] on the
resulting zero-floored Z-score matrix, and found that three sub-
groups of case drugs clearly interacted selectively with three
different sub-groups of proteins (step 2 Figure 1), implying that the
three different sub-groups of case drugs might trigger the SJS/
TEN through three different mechanisms. Then we divided the
case matrix into three sub-CPIs, and performed a trimming
procedure to exclude the redundant case chemicals if multiple
forms of a drug were clustered into the same sub-CPI. To identify
proteins preferentially interacting with the case drugs, we
performed Fisher’s exact tests followed by false discovery rate
(FDR) corrections [24] for every sub-CPI in comparison to the
control group. This non-parameter test only required binding
information in a binomial pattern, which could be specifically
measured by Z-score. In sub-CPI 1 (step 3 of Figure 1), p and q
values [24] for each proteins were calculated. As a result, HLA-
Cw*4 heavy chain (1QQD) together with other proteins were
highlighted. In sub-CPI2 and sub-CPI3, leukotriene A4 hydrolase
(1HS6), CD26 (2G5P) and Fab9 fragment of IgG (1DBJ) together
with other proteins were identified (step 4, 5 of Figure 1).
Identification of biological processes from the SJS/TEN-
oriented gene co-citation network
We further enriched the biological process (BP) terms of Gene
Ontology (GO) from the gene co-citation network (GCCN) [25].
We downloaded 18566 SJS/TEN-related PubMed entries,
calculated the citation rates for each of the human genes in
SJS/TEN related and nonrelated PubMed entries. Genes cited
more specifically in the SJS/TEN topic were defined as core
genes. Two genes were connected if they were co-cited in a
PubMed entry (step 6 of Figure 1). To retrieve a more delicacy set
of GO BP terms for SJS/TEN, we extended the core gene set
through indexing their neighbors in GCCN. For example, LTA
was one of the neighbors of the core gene HLA-C [26]. Though
had not been investigated in SJS/TEN, LTA was co-cited with
HLA-C [27], implying a putative functional linkage of this gene to
SJS/TEN through HLA-C. Both the extended and the core genes
were used in the enrichment analysis of BP terms [28]. As shown
in step 6 of Figure 1, genes annotated with ‘‘immune response’’
(p=8.32E-07), ‘‘inflammatory response’’ (p=2.48E-18) and ‘‘T
cell activation’’ (p=1.02E-41) tended to occur more frequently in
SJS/TEN-oriented GCCN than random selection at a significance
level of 0.01.
Highlighting the candidate genes for serious cutaneous
reactions
Finally, the BP terms were assigned manually to proteins
highlighted from sub-CPIs. Proteins were defined as the class I
candidates if they shared the same BP terms enriched from
GCCN. Otherwise they were defined as class II candidate. Class I
candidates were involved in the known biological processes of
SJS/TEN while class II proteins did not. However, it does not
mean that class II candidates are less important since human
knowledge on SJS/TEN is still limited. MHC I protein heavy
chain Cw*4 (1QQD) showed the lowest p value in the candidate
list. It is assigned as a class I candidate, as it was annotated with
the BP terms ‘‘immune response’’ (GO:0006955) and ‘‘antigen
processing’’ (GO:0019882), which were highlighted from the
GCCN. When investigated the interaction strength among all
case-control drugs and HLA-Cw*4 (Table S3), we found that 85%
(11 of 13) case drugs including 9 sulfonamides bind strongly to it.
Table S4 showed significant differences between case and control
interactions with HLA-Cw*4 either in docking scores or in Z-
scores. By visualizing the binding conformations at the lowest
energy, we found that all sulfonamides tended to ‘‘root’’ at MHC
I’s antigen presentation groove through the hydrogen bond
interaction of sulfuryls to the two arginine residues (Figure 2B).
This identification of HLA-C (w*4) as the mediator of sulfameth-
oxazole (SMX)-induced TEN was validated by other studies, as it
was confirmed that the immune response and the TEN will only
be triggered by SMX in presence of MHC I (Cw*4) [26,29].
Following the same data-mining and text-mining pipeline, we
identified candidate genes from the other two sub-CPIs (Table 1).
Two representative proteins highlighted were leukotriene A4
hydrolase (1HS6) and Fab fragment of IgG (1DBJ). The former is
the rate-limiting enzyme in formation of leukotriene, which
transduces the signal of inflammation in skin reactions [30]. Case
drugs tend to bind to its peptidase active center and might
interfere the suicide regulation [31] of the enzyme itself when the
enzyme is over-expressed. Case drugs in sub-CPI 3 tend to bind to
the variable region of a certain IgG. We could not deduce the
downstream events of this binding, but it has been known that the
binding of antigens to the IgG induces the release of leukotriene,
activate alexin system and the type III hypersensitivity.
Identification of the candidate risk alleles of serious
cutaneous reactions through insight into the CPI
The CPI would not only tell which protein to mediate the
SADR, but would also tell which allele of this protein would be
more sensitive to the unexpected drug attack. To our knowledge,
HLA-B*57 is the only reliable susceptibility gene of SADRs
[32,33] of which structures with both risk and non-risk alleles are
available. We constructed an interactome including interaction
strength among abacavir, allopurinol and four structures of risk
and non-risk alleles of abacavir-induced hypersensitivity (Table 2).
No specificity of allopurinol to any of the proteins was found. This
result was in coordination with the fact that none of these alleles
was the risk allele of allopurinol-induced hypersensitivity, In
contrast, abacavir did not accommodate the binding site of
B*5703, but appeared to have the high affinity with B*5701. The
major difference between the two alleles lay in two polymorphisms
(N114D, Y116S) from B*5703 to B*5701. When Y116S
substitution appeared in B*5703, a better compatibility of
geometry shape between drug and binding pocket as well as
several hydrogen bonds were formed. As a result, abacavir
molecule fixed deeply into the antigen presentation groove of
HLA-B*57 (Figure 3, Video S2). Comparatively, the N114D
seemed to be less important for the substitution of a nitrogen atom
to an oxygen atom would neither affect the steric hindrance nor
did the buildup of hydrogen bonds. Given the premise that direct
binding of drug to HLA-B*57 protein mediates abacavir-induced
hypersensitivity, we deduced that B*5701 tended to be the risk
allele compared to B*5703. The discovery of the fact that abacavir
Chemical-Protein Interactome Adverse Drug Reaction
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th and 116
th residues of MHC I B*57
which mediates SJS is consistent with the genetic evidences [32–
35]. This newly identified molecular mechanism has also been
validated at the cell biology level [36]. In the presence of abacavir
and MHC I (B*5703), the percentage of responding IFNg+ CD8+
T cells was only 1.34%, and the percentage remained unchanged
when N114D mutation was introduced. However, this percentage
suddenly rose to 28.4% when another mutation Y116S, which
formed the risk allele B*5701, was introduced. The result fit the
drug-MHC I direct binding model for that Y116S was essential to
the binding of abacavir, and N114D tended to be less important.
Identification of candidate genes associated with
cholestasis, rhabdomyolysis and deafness
A systematic insight into the CPI led to the identification of the
SADR targets common to case drugs, and the risk alleles of them
as well. We thus explored SADR targets for three other SADRs
using the same methodology (Table 1). The relationships among
drugs, SADR outcome and the corresponding sub-CPI were listed
in Table S5. Vasopressin receptor was highlighted from
cholestasis-related CPI. Being the native ligand, administration
of vasopressin could result in a reduction in bile flow and then
induce cholestasis [37]. Troponin T and PAK1 protein kinase
were harvested as well. The former regulates muscle contraction
while the latter, inhibited by most statin drugs in the rhabdomy-
olysis-oriented CPI, takes a vital part in the polymerization and
depolymerization of actin. Energy dysfunction plays an important
role in pathogenesis of hearing loss [38]. We found that, compared
with other SADRs, deafness is significantly associated with
proteins contributing to energy metabolism (see note of Table 1).
The consistently higher than random recall rates of proteins
known to be related to SADRs indicates that all these results could
not have been achieved by chance.
CPI profile of a drug reflects its interacting character
towards multi-protein set
Network pharmacology [39] pointed out that many drug effects
are mediated by the chemical-protein interactions of drugs
towards multi-protein set. The SADR might also be triggered by
the combination effect of drug-SADR target interactions. So we
hypothesized that drugs causing the same SADR not only share
the same SADR targets, but might also possess the similar binding
strength profile towards multi-protein set. If this similarity can be
detected, we may infer that the CPI not only represent the binding
situation of a drug to a protein, but also reflect the interacting
character of it towards multi-protein set. Here we utilized support
vector machine (SVM) model to see whether drugs could be
correctly classified as case or control drugs based on their binding
profile vector against 845 proteins. If they could be, there was a
similarity in high-dimensional space among case drugs or control
drugs towards 845 protein set. The effectiveness of the classifier
was measured by the binary classification accuracy using cross
validation. For each SADR, categorical attributes of case or
control drugs were labeled as ‘‘1’’ or ‘‘0’’. Z-score of a drug
towards 845 proteins was used as the attribute vector. The cross
validation accuracy (CVA) varied from 85% to 91% among four
SADRs (Table 3). To evaluate whether such CVAs were achieved
by chance, we permutated the position of the case and control
drugs randomly for 100 runs, and recalculated the mean CVAs.
The mean CVAs of permutated data turned out to be much lower
(Table 3). So we concluded that there were similarities among
drugs with the same outcome of an SADR, which were found in
the CPI profile of them towards multi-protein set.
Discussion
The basic hypothesis of the CPI
The hypothesis that drugs with similar phenotypic effects tend
to interact with same targets is similar to a recent study done by
Campillos et al [40]. However, the target spaces and the aims of
the two studies are different. The work of Campillos et al managed
to construct new connections among drugs and known therapeutic
targets, which are a small portion of protein spaces whose
functional information is clearly identified. Our research tried to
construct new connections among drugs and human proteins,
which is a step into a larger protein space whose function needs
further exploration. However, our methodology is hampered by
the lack of the structurome information of the human proteins.
The aim of the former research is to explore the off-targets. For
our research, the major aim of finding the off-targets is to figure
out the key interacting residues and the risk allele for each
individual.
Unexpected drug-protein interaction is the vital step in
pathogenesis of SADRs. Although drug response is a complex
trait [1] mediated by multiple genes and their interactions, some
well-known cases of polymorphism within a gene have pro-
nounced effects on drug response. To our knowledge, all of these
polymorphisms alter the pattern of direct chemical-protein
interactions. Examples include the T790M mutation in the
gefitinib binding pocket of EGFR [41]; the T164I mutation
within the epinephrine binding pocket of b2-adrenergic receptor
[42]; and the polymorphism within binding pocket of STI-571 to
c-Abl [43]. Although multiple genes take part in immune response
only the HLA genotypes are significantly associated with SJS
[22,32,33,44,45]. Such a strong linkage suggests that a direct
binding of SADR-causing drugs to MHC I may be the primary
event. In the case of HLA-Cw*4, all sulfonamides bind to the
antigen presentation groove. Several ‘‘wet’’ observations support
Figure 1. Strategy of identifying candidate genes for SADR through data-mining against the CPI and text-mining. Step (1) Drugs
retrieved from adverse events reporting system of FDA were docked into the active sites of proteins. Shown here are the binding conformations of
the four forms of fluoxetine (FXT1: the parent drug; FXT2: the major metabolite norfluoxetine; FXT3 and FXT4: nitrogen-atom positively charged of
FXT1 and FXT2 respectively) to the bioactive sites of the five proteins. Step (2) Visualization of clustering results against the case matrix of binding
affinity between 53 drugs (columns) and 845 proteins (rows). All case drugs were known to cause SJS/TEN. A Z-score greater or less than 21.2 were
represented as white or black squares respectively. Step (3) A local CPI. Interactions of 13 case drugs in the sub-CPI1 and 17 control drugs with five
proteins were shown here. For each of the proteins, the number of case drugs that interact with it with a Z-score,21.2 (dark blue square) or with Z-
score.21.2 (black) were denoted as a and c, whereas the number of control drugs that interact with it with a Z-score,21.2 (light blue) or with a Z-
score.21.2 (gray) were denoted as b and d, respectively. Step (4) & (5) Representative proteins highlighted from sub-CPI2 and sub-CPI3. The
number of case or control drugs varied because of the missing values. Step (6) A local SJS/TEN-oriented GCCN. Yellow diamonds and white circles
represent the core genes and extended genes respectively. One PubMed entry [26] (yellow bolded) referring to HLA-C mainly deals with TEN. Another
entry [27] (red bolded) describes the relationship between HLA-C and LTA (red line). Genes that are annotated with GO term ‘‘inflammatory response’’
(in purple rectangle), ‘‘T cell activation’’ (blue) and in ‘‘immune response’’ (red) tend to be cited more specifically in this GCCN. Step (7) If a protein
highlighted from the CPI share the GO terms enriched from GCCN, its symbol is presented in the corresponding color of the GO terms in step (6).
doi:10.1371/journal.pcbi.1000441.g001
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PLoS Computational Biology | www.ploscompbiol.org 5 July 2009 | Volume 5 | Issue 7 | e1000441Figure 2. The interaction of sulfonamides to MHC I (Cw4). (A) Interaction strength among case drug molecules of SJS/TEN and MHC I (Cw*4).
Drug names followed by the numbers represent the derivatives of this drug. In sub-CPI 1, 15 molecules interact strongly with MHC I (Cw*4). After
trimming procedure, 13 case drugs including 9 sulfonamides (listed in C) were found binding to MHC I (Cw*4). (B) The lowest energy conformations
of four sulfonamides’ binding to the antigen presentation groove of MHC I (Cw*4) through hydrogen bonds between the oxygen atoms in sulfuryls
to the nitrogen atoms in the two arginine residues (R97 and R156). Residues in the two a-helixes also contribute to the binding. The four
sulfonamides shown here are bumetanide, celecoxib, sulfadoxine and sulfamethoxazole. See Figure S2 for the binding conformations of other
sulfonamides. (C) The nine sulfonamides have different structures, but they all bind to the two stretched arginine residues through their sulfuryls as
the ‘root’. Molecular structures of the 17 control drugs which do not tend to interact with MHC I (Cw*4) were shown in Figure S3.
doi:10.1371/journal.pcbi.1000441.g002
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sulfamethoxazole (SMX) parent drug displayed a direct, non-
covalent binding fashion to the MHC–peptide complex [46].
Secondly, the antigen peptide within the MHC I groove does not
appear to be essential, since the elution of the peptide did not
affect the presentation of SMX [47], thus there might be
competitive binding between the drugs and the peptide to the
groove. Thirdly, von Greyerz et al [29] found that most T cell
clones showed a ‘‘MHC-allele restricted drug-specific recognition’’
that was stimulated by the parent drug rather than its derivatives.
Fourthly, Nassif [26] discovered that blister fluid T lymphocytes,
which were derived from a patient suffering SMX-induced TEN,
were cytotoxic only when SMX is present and the cells share
HLA-Cw*4. This HLA allele-drug specific cytotoxicity was
confirmed in another study [48], and can be abrogated with the
change of a single residue in the groove. Finally, the S116Y within
HLA-B*5701 was shown to hamper completely the presentation of
abacavir [36], suggesting that the drug itself, or a metabolite,
might be accommodated in the groove and the residue is essential
for this binding. All these facts corroborate the direct drug-protein
interaction model in which the strong MHC allele-drug specificity
could be best explained by a steric complementarity together with
other strong non-covalent interactions between the drug molecule
and the antigen presentation groove. The groove contains a
variable region where MHC I molecules coded by thousands of
HLA alleles differ and the antigen peptide-MHC I recognition
takes place. In our model, a similar drug-MHC I recognition
occurs when the drug binds to its specific ‘‘port’’ of a particular
MHC allele at the variant region. This specificity could also be
found at the genetic level. For example, severe cutaneous adverse
Table 1. Candidate proteins mediating the four SADRs.
SADR PDB Protein Name GO ID GO Term pq
a ab c d
sub-
CPI Class
SJS/TEN 1QQD HLA-Cw*4(Heavy Chain) GO:0019882 antigen processing and
presentation
2.15E-05 2.98E-05 11 0 2 17 1 I
SJS/TEN 2G5P CD26 (DPP4) GO:0042110 T cell activation 9.39E-04 0.0124 7 3 1 16 2 I
SJS/TEN 1HS6 Leukotriene A4 hydrolase GO:0006954 inflammatory response 0.0202 0.0280 7 8 0 10 2 I
SJS/TEN 1DBJ Fab9 Fragment of IgG N/A N/A 0.000439 0.00889 12 7 0 12 3 II
rhabdomyolysis 1B09 C-reactive protein GO:0006953 acute-phase response 0.000135 0.00622 7 3 0 17 2 I
rhabdomyolysis 1DTL Troponin T, Cardiac Muscle Isoforms GO:0006937 regulation of muscle contraction 0.000182 0.00622 7 3 0 16 2 I
rhabdomyolysis 1F3M PAK-1 protein kinase GO:0008154 actin polymerization and/or
depolymerization
0.00342 0.0177 4 0 4 20 1 I
rhabdomyolysis 2DDH Acyl CoA oxidase 2 GO:0006629 lipid metabolic process 0.0235 0.0472 5 4 2 16 2 I
deafness 1BQS Mucosal Addressin Cell Adhesion
Molecule 1
GO:0007155 cell adhesion 5.93E-05 0.000597 10 2 3 21 2 I
deafness 1P4M Riboflavin Kinase* GO:0009231 riboflavin biosynthetic process 0.000322 0.00204 8 1 5 22 2 I
deafness 1IG3 Thiamin Pyrophosphokinase* GO:0006772 thiamin metabolic process 0.000411 0.00236 9 2 4 20 2 I
deafness 1JJC Phenylalanyl tRNA Synthetase GO:0006412 translation 0.000434 0.00244 12 7 1 16 2 I
deafness 1JKL Death-Associated Protein Kinase GO:0006915 apoptosis 0.000920 0.00415 10 4 3 19 2 I
deafness 1BU5 Flavodoxin* GO:0006810 transport 0.00636 0.0171 8 3 5 20 2 I
deafness 1EFR Mitochondrial F1-ATPase* GO:0006754 ATP biosynthetic process 0.00573 0.0206 7 5 2 18 1 I
cholestasis 1HN4 Prophospholipase A2 GO:0006633 fatty acid biosynthetic process 0.000347 0.0131 6 1 1 16 1 I
cholestasis 1HN5 Prophospholipase A3 GO:0050482 arachidonic acid secretion 0.000939 0.000939 7 1 3 16 2 I
cholestasis 1YTV Vasopressin V1a receptor GO:0006810 transport 0.000171 0.00531 11 4 1 15 3 I
See Table S5 for the full list of other class I and class II candidates.
*Proteins contributing to energy metabolism specifically appeared in the protein set prioritized from deafness-oriented CPI (p=0.0050, Chi-square test, two-tailed).
aThe q value was calculated using the FDR correction algorithm [24].
doi:10.1371/journal.pcbi.1000441.t001
Table 2. Interactome among abacavir, allopurinol and four HLA-B*57 molecules.
PDB ID Allele Dock Score
a Z-score Is Risk Allele Dock Score
b Z-score Is Risk Allele
2BVO B*5703 233.73 0.460 No 226.95 1.77 No
2BVQ B*5703 234.07 0.416 No 228.56 0.141 No
2BVP B*5703 232.52 0.618 No 226.88 1.84 No
2RFX B*5701 248.71 21.49 Yes 228.69 0.00565 No
aDocking score for drug abacavir.
bDocking score for drug allopurinol.
doi:10.1371/journal.pcbi.1000441.t002
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of B*5801 [44]; abacavir-induced skin reaction requires the
parallel genotype of B*5701 [32]; and carbamazepin-induced SJS
is linked to B*1502, but not to HLA-A*1101 [45]. All these
markers have a pronounced predictive capability of SADRs,
leading the U.S. FDA’s recommendation for their implementation
for personalized medicine. The growing body of evidence suggests
that the direct chemical-protein binding may enable the
identification of more promising markers for SADR genetics,
especially for predicting the specific HLA alleles that may be
responsible for other drug-induced hypersensitivity, and finally, for
a better design of new drugs or the modification of existing drugs
to prevent these unintended interactions.
Availability and limitations of the CPI related techniques
Unexpected drug-protein interactions should be explored with
any available technologies such as drug affinity pull-down [9] or
compare the similarities of pocket shapes between known drug
target and the off-target [49]. However, in a drug affinity pull-
down experiment, it remains a challenging task to prioritize the
candidate proteins and to explain the biological significance when
hundreds of proteins are identified to be compatible to the drug.
The CPI methodology of finding the common SADR target could
enlighten the design of these ‘‘wet’’ experiments. For example, a
pull-down through a mixture of resins immobilized by different
case drugs might help to enrich the common targets, while the
follow-up pull-down using resins immobilized by control drugs
might exclude the false positives. Though DOCK could tell true
bindings from the unidentified ones, no strict assessment had been
put forward as to the resolving power of its scoring functions to
evaluate the degree of the interaction strength of CPI. The lack of
human protein structures is another problem. An ideal chemical-
protein interactome would include the 3D structures of all human
proteins whose structural flexibility can be effectively handled by
more advanced docking programs so that the binding affinity can
be better estimated. This would lead to a whole structurome-wide
study with more unexpected interactions to be identified. Because
of the biases in the structural and functional coverage in PDB and
our pocket preparing criteria, the 845 proteins might not be
representative, some of which were even redundant. The lack of
randomization might introduce biases in the statistical model.
Instead, preparing a reference protein set from other structural
databases, e.g., choosing one representative structure for each
SCOP super family [50], might improve the model. However, our
pocket preparing criteria could guarantee all the proteins were
targetable. Preserving the redundancy also enabled us to disclose
more flexibility information of the protein cavities. Although this
protein set needed improvement, with these structures, we were
still able to i) highlight the true bindings from the unidentified
bindings; ii) identify the susceptibility gene (HLA-Cw*4) for the
SMX-induced TEN without any prior knowledge of the
underlying mechanism; iii) identify the candidate risk allele of
the susceptibility gene (HLA-B*5701) based on the direct drug-
MHC I interaction model which had never been proposed in all
drug-induced hypersensitivity models. In addition, many candi-
date SADR targets prioritized from the CPI tended to be linked to
Table 3. Comparison of the cross-validation accuracy (CVA) between the original dataset and the randomly permutated dataset.
SADR Total Sample ## of Case Drugs # of Control Drugs CVA (%)
a Mean CVA (%) of permutations
SJS 82 53 29 90.8 62.3
cholestasis 87 57 30 85.2 59.1
deafness 88 48 40 87.5 59.8
rhabdomyolysis 90 49 41 91.4 54.3
aPrediction models of the four SADRs shown here were validated by 5-fold cross validation.
Both case and control drug group contain the derivatives.
doi:10.1371/journal.pcbi.1000441.t003
Figure 3. Models of abacavir’s interactions with the binding site of HLA-B*5703 and HLA-B*5701. (A) The abacavir could not bind to the
antigen presentation groove of MHC I (B*5703, PDB ID: 2BVP). No non-covalent interaction could be formed with N114 in the presence of Y116 due to
the steric hindrance (Video S1). (B) The steric hindrance of the binding disappeared when Y116S was introduced. The binding score between abacavir
and MHC I (B*5701) was much lower than with (B*5703) because of I) better compatibility of geometry shape to the binding pocket; II) hydrogen
bonds (yellow dashed) were formed with three essential AA residues (D114, S116 and T143) within the antigen presentation groove (Video S2).
doi:10.1371/journal.pcbi.1000441.g003
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selection. As ‘‘wet’’ techniques for building up the CPI is not
mature, the in silico approach appears to be the only means feasible
to apply the CPI at the prescreening level, considering the urgency
of the global SADR problem. Though false positive candidate
genes might also be proposed, they can be controlled in different
data transformation steps. Firstly, if one ligand tends to give low
docking scores, it is usually caused by the ligand factor which could
be eliminated in the normalization steps. Secondly, if one target
tends to give low docking scores, it could raise low score for both
case and control drugs. So this target cannot achieve a low p value
in Fisher’s exact test, and cannot be highlighted in the CPI.
Thirdly, the false positive given by p value judgment could be
controlled by the FDR correction. Lastly, they can be eliminated
through association studies of the SADR patients or the functional
studies of the SADR mechanisms, just as the docking procedure
for identifying drug candidates is always followed by the binding
affinity experiments.
One limitation of our SVM classification model is the number
of control samples in SJS/TEN group. We did not managed to
find enough SJS- drugs to construct a sample set with case-control
ratio at 1:1. SJS seems to be particular that only a few drugs do not
linked with it. We could not find enough independent validation
set either due to our strict criteria of the sample selection. This is
the first try of using CPI profile to predict ADR outcome of a drug,
the prediction performance of the CPI thus needs further
validation and the model needs to be optimized. However, the
permutation result added some reliability to the classification
model. Compared with the permutation result, the classification
result showed there were similarities in the CPI profiles of the case
drugs, which provided hint for the construction of the prediction
model based on this methodology.
Comparison with other techniques
Although case drug molecules in Fig. 2B shared some structure
similarity, the high-dimension information provided by CPI
extends beyond simple structural comparison. Take fluoxetine 4
and fluoxetine in Fig. 2A for example, only a simple change in the
ionization state between the two molecules will give different CPI
profiles, with the distance between the two molecules far on the
clustering tree. The chemical-protein interactomic analysis might
also be complementary to trascriptomics in toxicogenomics. The
latter provides a rich description of cell status [51], whereas the
CPI strategy seems to provide more direct and interpretable
biological understandings. The primary interactions of a drug to
proteins are the causes of biological events, whereas the
trascriptome strategy only detects the resulting phenotypes.
Knowing which proteins’ function are disabled and which alleles
tend to be disabled by the drugs are vital, for they might lay a
direct solution to SADR at the source.
Perspectives
Usually we could only access ‘‘wild-type’’ protein structures, and
it is not only possible but also necessary to simulate genetic
variability in 3D structures and thereby discover patient-specific
off-targets so that we can predict one’s SADR or drug effect from
their ‘‘structypes’’. However, we cannot construct a CPI that only
uses the modeled ‘‘structypes’’, since the type I error might
accumulate significantly. So our strategy is to find proteins tend to
be highlighted in a CPI containing ‘‘wild-type’’ structures, and
then investigate whether the allele of the highlighted ones could
constitute a risk allele.
The SADR genetics requires worldwide collaboration [52,53].
At a time when samples are rare and the primary mechanisms are
unclear, both the sample information and the hypothesized
candidate genes should be shared by the community for
prospective experimental validation. Thus, in anticipation of this
global collaboration, we made the statistically significant candidate
genes highlighted from CPI (Table S6) publicly available for
SADR consortia’s consideration, verification and the improve-
ment of CPI methodology. We expect that the perfection of CPI
will eventually benefit the public by understanding, minimizing
and predicting the occurrence of SADRs.
Methods
Preparation of the protein pocket set and the ligand set
We selected targets from literature and from third-party
targetable protein databases [14–17]. Every pocket had been
examined manually and was screened according to the criteria
pre-defined: I) In order to identify unexpected drug-protein
interactions, the target space should not be confined to the narrow
space of the targets for the marketed drugs, which are merely a
small portion of all protein spaces. II) To utilize the structure space
to the max, the species of the protein should not be confined to
Homo Sapiens, and the homolog protein can be considered.
Targets with greater than 30% in protein sequence similarity to
the corresponding human protein at the bioactive site could be
chosen. III) The PDB structure should contain the co-crystallized
ligand to define the bioactive site and to indicate the protein is
targetable, PDB entries whose ligand is at the surface of the
protein are not acceptable. IV) The ligand embedded in the PDB
structure should achieve certain rigidity and some specificity
towards the target, e.g., compounds with a large portion of
rotatable bonds were not acceptable. V) No missing residue should
be around the bioactive site. Residues within 10 A ˚ departed from
the ligand were defined as the bioactive pocket of the protein, and
balls with radius ranging from 1.1–1.4 A ˚ were generated to fill in
the pocket. Grid box was made 3–5 A ˚ departed from the ‘cloud’ of
the balls.
The SMILES information of the small molecules was retrieved
from PubChem. The minimal energy conformations of chemicals
were generated with CORINA. All structures of proteins and
chemicals were prepared using Chimera [54] and PyMOL. All the
above procedures were performed manually with a strict quality
control.
Construction of the test CPI
An intersection operation was performed between all drug
targets in DrugBank and the proteins in our pocket set using PDB
id or Uniprot id as the identifier. We confirmed that each of the
proteins in intersection had at least two FDA-approved drugs bind
directly to them with a clear pharmacology to insure that they
were credible drug targets. The running of the DOCK program
and the extraction of the results were controlled by Perl or shell
scripts on a Ubuntu
TM Linux cluster. The docking score was
calculated as the sum of intramolecular and intermolecular energy.
A docking score greater than zero was treated as a missing value.
There were a total of 845 proteins with 891 pockets in our pocket
set. When a protein has multiple pockets to bind with, only the
lowest docking score was chosen as the reference score, so the
docking score matrix was shrunk to 466845 elements. Here Xij
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where Nj equals 845 minus the number of missing docking value of
drug j to the protein set. So a Z-score matrix of 466845 elements
was generated. All direct bindings verified in literature or in the
‘‘description, indication, pharmacology and mechanism_of_ac-
tion’’ fields of DrugBank database were defined as group 1,
whereas other unidentified bindings were designated as group 2.
The nonparametric Mann-Whitney test was performed on the Z-
scores.
Construction of a SADR oriented-CPI
All accessible AERS raw data from Jan 2004 to Mar 2008 were
downloaded from FDA website and then deposited into a
relational database (MySQL 5.1.22). In an SADR report, only
the primary or the secondary suspected drugs were regarded as
linked to the reported SADR. Drugs reported in the literature to
have caused a SADR were further examined in AERS; only those
reported in the AERS more than three times were considered as
case drugs. The candidates for control drugs were collected on
condition that they had never been co-cited with this SADR in the
literature. They were classified into control group only if the report
number was zero or less than 5% of its total reports when jointly
used with the case drugs. The Z-score matrix was generated using
the same pipeline as described above. However, for the SADR








where Zij was the interaction strength between drug j and protein
i. The Pearson correlation coefficient r between the two columns of





























where N represents the number of Z9 value pairs of drug j1 and
drug j2 with no missing value. Z0
j1 and Z0
j2 are the average Z9-score
of drug j1 and j2, whereas SDZ0
j1 and SDZ0
j2 are standard
derivation of Z9-score of the two drugs. The hierarchical clustering
was then performed based on the r values between each pair of
drugs. In the trimming procedure within each sub-CPI after
clustering, only molecule with the lowest mean Z-score was chosen
when multiple forms of a drug were clustered into the same sub-
CPI. For protein i, ai, bi, ci, di values, representing the number of
binding (ai or bi) and non-binding (ci or di) by case drugs or control
drugs respectively, were counted and the relative risk (RR) value









Protein targets with a RR value exceeding 1 were chosen for
Fisher’s exact test, as the expected values in any of the ai, bi, ci, di
value sometimes is below 10. The p values were then corrected
using fdrtool package [55] of R to control the false positives.
Construction of SADR-oriented GCCN and enrichment
analysis of GO terms
Although a more reliable network might be constructed using
the STRING server [56], it is still uncertain that whether its
physical and functional relationships can denote the true situation
in SADR pathology. However, it could be more certain that a
gene is involved in an SADR if it is cited specifically in this SADR
related literature. So we only chose GCCN to organize the SADR
related knowledge in a gene-oriented fashion. Four sets of PubMed
entries were retrieved through the following four querying terms:
Cholestasis; Deafness OR ‘‘hearing loss’’; rhabdomyolysis OR
myalgia OR myopathy OR myositis; rash OR Stevens-Johnson
syndrome OR toxic epidermal necrolysis. The records were
downloaded in XML format through the eSearch and eFetch
APIs, and were deposited into a MySQL database. The index file
of human genes to PubMed entries was downloaded from the
Entrez Gene ftp site. A core gene of SADR ‘‘S’’ must meet one of
the two criteria: the citation rate of this gene in this ‘‘S’’-related
corpus must exceed its citation rate in corpus under other topics;
the number of citation must exceed four. A connection between
two genes was established in GCCN if they were co-cited in more
than two PubMed entries. Both core genes and extended genes of
‘‘S’’ were included in enrichment analysis of biological process
(BP) GO terms using EASE [57]. The p value generated from
Bonferroni correction was used as a measure in choosing the
significant BP terms. The GO terms of each candidate proteins
highlighted from CPI were assigned through querying the Gene
Ontology Annotation database [58] with their UniProt ID as the
identifier. Attributes of candidate class (I or II) were assigned
manually depending on whether the candidate targets had shared
the BP terms enriched from the GCCN.
Construction of the binary classification model using the
CPI profile
For each SADR, categorical attribute of a drug was labeled as
‘‘1’’ or ‘‘0’’ if it could (SADR+) or could not (SADR2) trigger this
SADR. Z-scores were chosen as a measure of the interaction
strength. Then for each protein, Z-scores were linearly scaled to
the range of [21, 1]. We chose a nonlinear RBF kernel function to
build the model, because the relations between class labels and
interactome attributes are nonlinear, and this kernel function,
K(Xi,Xj)~e({cjjXi{Xjjj
2),cw0,
could map vectors onto a higher dimensional space nonlinearly.
Here C and c were two essential parameters for RBF function, but
it was not known beforehand that which C and c fitted best for our
model. We performed the exhaustive searching for the best (C, c)
pair each time we performed the 5-fold cross-validation test.
Supporting Information
Figure S1 ROC curve of the Z-score and the dock score in
identifying the true bindings.
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Figure S2 The lowest energy conformations of five sulfon-
amides’ binding to the antigen presentation groove of MHC I
(Cw*4). These five sulfonamides are piroxicam, sulfasalazine,
tenoxicam, valdecoxib and tolbutamide. See Fig. 2C for the
molecular structures of these drugs.
Found at: doi:10.1371/journal.pcbi.1000441.s002 (0.44 MB
DOC)
Figure S3 Molecular structures of the 17 control drugs which do
not tend to interact with MHC I (Cw*4).
Found at: doi:10.1371/journal.pcbi.1000441.s003 (0.16 MB
DOC)
Table S1 Target set of the CPI.
Found at: doi:10.1371/journal.pcbi.1000441.s004 (0.03 MB
TXT)
Table S2 Mann-Whitney test of true positive bindings to the
unidentified bindings on their Z-scores.
Found at: doi:10.1371/journal.pcbi.1000441.s005 (0.03 MB
DOC)
Table S3 The interaction strength among case-control drugs
and HLA-Cw*4.
Found at: doi:10.1371/journal.pcbi.1000441.s006 (0.06 MB
DOC)
Table S4 T-test for equality of means on dock score and Z-score
of HLA-Cw*4-oriented interactions between case drugs and
control drugs.
Found at: doi:10.1371/journal.pcbi.1000441.s007 (0.04 MB
DOC)
Table S5 Drug molecules within each sub-CPIs after the
trimming procedure.
Found at: doi:10.1371/journal.pcbi.1000441.s008 (0.12 MB
DOC)
Table S6 Candidate proteins for the four SADRs.
Found at: doi:10.1371/journal.pcbi.1000441.s009 (0.35 MB
DOC)
Video S1 Binding model of abacavir-MHC I B*5703.
Found at: doi:10.1371/journal.pcbi.1000441.s010 (7.40 MB
MOV)
Video S2 Binding model of abacavir-MHC I B*5701.
Found at: doi:10.1371/journal.pcbi.1000441.s011 (7.43 MB
MOV)
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